Diagnostic capacity for fungal keratitis in Africa – Survey in 50 African countries

Makangara Cigolo, Jean Claude; Oladele, Rita O.; Kennedy, Stephen B.; Bignoumba, Michelle; Hassane, Hassane Mahamat; Bucumi, Victor; Kamwiziku, Guyguy; Eduful, Stephen Kojo; Afonso Manjate, Alice; Isse Mohamed, Sahra; Mbise, Furahini; Shisholeka, Mutinta E.; Penney, Richard O.S.; Orefuwa, Emma; Denning, David W.

doi:10.1016/j.jtos.2023.08.010

Cited by 2 publications

(1 citation statement)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 115 Across Africa, diagnostic procedures for sample collection for pathogen identification remain a major limitation in the diagnosis of fungal keratitis. 116 …”

Section: Discussionmentioning

confidence: 99%

Re-estimation of the burden of serious fungal diseases in Uganda

Bongomin,

Kwizera,

Namusobya

et al. 2024

Therapeutic Advances in Infection

Self Cite

View full text Add to dashboard Cite

Background: It is of utmost importance to monitor any change in the epidemiology of fungal diseases that may arise from a change in the number of the at-risk population or the availability of local data. Objective: We sought to update the 2015 publication on the incidence and prevalence of serious fungal diseases in Uganda. Methods: Using the Leading International Fungal Education methodology, we reviewed published data on fungal diseases and drivers of fungal diseases in Uganda. Regional or global data were used where there were no Ugandan data. Results: With a population of ~45 million, we estimate the annual burden of serious fungal diseases at 4,099,357 cases (about 9%). We estimated the burden of candidiasis as follows: recurrent Candida vaginitis (656,340 cases), oral candidiasis (29,057 cases), and esophageal candidiasis (74,686 cases) in HIV-infected people. Cryptococcal meningitis annual incidence is estimated at 5553 cases, Pneumocystis pneumonia at 4604 cases in adults and 2100 cases in children. For aspergillosis syndromes, invasive aspergillosis annual incidence (3607 cases), chronic pulmonary aspergillosis (26,765 annual cases and 63,574 5-year-period prevalent cases), and prevalence of allergic bronchopulmonary aspergillosis at 75,931 cases, and severe asthma with fungal sensitization at 100,228 cases. Tinea capitis is common with 3,047,989 prevalent cases. For other mycoses, we estimate the annual incidence of histoplasmosis to be 646 cases and mucormycosis at 9 cases. Conclusion: Serious fungal diseases affect nearly 9% of Ugandans every year. Tuberculosis and HIV remain the most important predisposition to acute fungal infection necessitating accelerated preventive, diagnostic, and therapeutic interventions for the management of these diseases.

show abstract

“… 115 Across Africa, diagnostic procedures for sample collection for pathogen identification remain a major limitation in the diagnosis of fungal keratitis. 116 …”

Section: Discussionmentioning

confidence: 99%

Re-estimation of the burden of serious fungal diseases in Uganda

Bongomin,

Kwizera,

Namusobya

et al. 2024

Therapeutic Advances in Infection

Self Cite

View full text Add to dashboard Cite

show abstract

The Impact of the Fungal Priority Pathogens List on Medical Mycology: A Northern European Perspective

Arendrup,

Armstrong-James,

Borman

et al. 2024

Open Forum Infectious Diseases

View full text Add to dashboard Cite

Fungal diseases represent a considerable global health concern, affecting over one billion people annually. In response to this growing challenge, the World Health Organization introduced the pivotal fungal priority pathogens list (FPPL) in late 2022. The FPPL highlights the challenges in estimating the global burden of fungal diseases and antifungal resistance (AFR), as well as limited surveillance capabilities and lack of routine AFR testing. Furthermore, training programmes should incorporate sufficient information on fungal diseases, necessitating global advocacy to educate healthcare professionals and scientists. Established international guidelines and the FPPL are vital in strengthening local guidance on tackling fungal diseases. Future iterations of the FPPL have the potential to refine the list further, addressing its limitations and advancing our collective ability to combat fungal diseases effectively. Napp Pharmaceuticals Limited (Mundipharma UK) organised a workshop with key experts from Northern Europe to discuss the impact the FPPL will have on regional clinical practice.

show abstract

Diagnostic capacity for fungal keratitis in Africa – Survey in 50 African countries

Cited by 2 publications

References 7 publications

Re-estimation of the burden of serious fungal diseases in Uganda

Re-estimation of the burden of serious fungal diseases in Uganda

The Impact of the Fungal Priority Pathogens List on Medical Mycology: A Northern European Perspective

Contact Info

Product

Resources

About